论文部分内容阅读
目的探讨内置引流管注射尿激酶治疗结核性胸腔积液的临床效果。方法选取2012年5月—2015年10月鹰潭市人民医院收治的结核性胸腔积液患者60例,随机分为观察组与对照组,各30例。两组患者均给予常规抗结核治疗,对照组患者给予胸腔内注射0.9%氯化钠溶液10ml,观察组患者在对照组基础上给予注射尿激酶20万U,两组患者均每周注射两次。比较两组患者胸腔积液引流量、胸膜厚度、住院时间、用力肺活量占预计值百分比(FVC%)、第1秒用力呼气末容积占预计值百分比(FEV1%)、治疗效果及不良反应发生情况。结果治疗后观察组患者腔积液引流量多于对照组,胸膜厚度小于对照组,住院时间短于对照组,FVC%、FEV1%高于对照组,差异有统计学意义(P<0.05)。观察组总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者均未发生严重不良反应。结论内置引流管注射尿激酶治疗结核性胸腔积液的临床效果确切,可有效缓解患者症状,改善患者肺功能。
Objective To investigate the clinical effect of drainage catheter injection of urokinase in the treatment of tuberculous pleural effusion. Methods From May 2012 to October 2015, 60 patients with tuberculous pleural effusion admitted to Yingtan People’s Hospital were randomly divided into observation group and control group, with 30 cases in each group. Two groups of patients were given conventional anti-TB treatment, the control group were given intra-thoracic injection of 10ml 0.9% sodium chloride solution. The patients in the observation group were injected with 200000 U of urokinase on the basis of the control group. Both groups were injected twice a week . Pleural effusion volume, pleural thickness, length of hospital stay, forced vital capacity (FVC%), forced expiratory volume at 1 second (FEV1%) were compared between the two groups. The treatment effect and adverse reactions Happening. Results After treatment, the effusion volume of hydronephrosis in the observation group was more than that of the control group. The pleural thickness was smaller than that of the control group. The length of hospital stay was shorter than that of the control group. The FVC% and FEV1% were higher than those of the control group (P <0.05). The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in both groups. Conclusion The built-in drainage tube injection of urokinase in the treatment of tuberculous pleural effusion clinical effect is exact, can effectively alleviate the symptoms and improve lung function in patients.